Objective: To compare the in vitro fertilization (IVF) outcomes of the progestin-primed ovarian stimulation (PPOS) protocol using dydrogesterone and the GnRH antagonist (GnRH-ant) protocol in POSEIDON group 4 patients.
Methods: This retrospective cohort study analyzed 447 POSEIDON group 4 patients who underwent IVF at a single center. Patients were categorized into GnRH-ant (n = 281) and PPOS (n = 166) groups. Propensity score matching was employed to balance baseline characteristics, yielding 165 patients in each group for comparison. The primary outcomes were the number and quality of cleavage and blastocysts embryos. Secondary outcomes included clinical pregnancy and ongoing pregnancy rates after the first frozen embryo transfer.
Results: Baseline characteristics were balanced between groups after matching. The PPOS group had a significantly lower number of good quality cleavage embryos (adjusted mean ratio 0.80, 95% CI 0.66-0.97) and blastocysts (adjusted mean ratio 0.77, 95% CI 0.62-0.96) compared to the GnRH-ant group. The number of cleavage embryos and good quality blastocysts was comparable between groups. Although not statistically significant, the clinical pregnancy (31.4% vs 36.8%) and ongoing pregnancy rates (20.3% vs 29.9%) after the first embryo transfer tended to be lower in the PPOS group.
Conclusions: In POSEIDON group 4 patients, the PPOS protocol using dydrogesterone may be associated with lower embryo quality and pregnancy outcomes compared to the GnRH-ant protocol. Further prospective randomized trials are needed to validate these findings.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jfma.2025.02.003 | DOI Listing |
Reprod Biol Endocrinol
March 2025
The Fertility Clinic, Skive Regional Hospital, Faculty of Health, Aarhus University, Skive, Denmark.
It is widely recognized that luteinizing hormone (LH) activity is pivotal during folliculogenesis. Nonetheless, the use of LH during ovarian stimulation remains a matter of debate. Indeed, women with good LH function are able to sustain follicle growth and maturation during ovarian stimulation carried out with regimens based on follicle-stimulating hormone (FSH) alone.
View Article and Find Full Text PDFJ Ovarian Res
March 2025
Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, 134, P. R. China.
Background: Poor ovarian response (POR) is a challenging condition in assisted reproduction technology. Oral contraceptives (OCs) are commonly used to suppress gonadotropin hormone release in POR patients to synchronize the development of antral follicles before ovarian stimulation. Nevertheless, the question of whether such approach confers advantageous outcomes has elicited inconclusive results in previous studies.
View Article and Find Full Text PDFMedicina (Kaunas)
February 2025
Department of Biology and Ecology, Faculty of Sciences, University of Novi Sad, Trg Dositeja Obradovica 2, 21000 Novi Sad, Serbia.
: POSEIDON 4 (P4) patients face the most adverse outcomes among poor responders. Oocyte donation has overcome unsatisfactory live birth rates (LBRs) in P4 patients and has become an indispensable approach. However, many patients refuse oocyte donation despite poor live birth likelihood using autologous oocytes.
View Article and Find Full Text PDFJBRA Assist Reprod
February 2025
Malopolski Institute of Fertility Diagnostics and Treatment - krakOvi, Krakow, Poland.
Objective: The aim of the study was to analyze the effectiveness of the day 3 ET strategy, and the morphology of the transferred embryos, in patients from POSEIDON and non-POSEIDON groups.
Methods: 600 cycles of patients meeting the POSEIDON criteria and 600 non-POSEIDON cycles were analyzed to determine the proportion of cycles with an ET on days 3 or 5, or FET. Then we reviewed 330 day 3 ETs to compared the developmental stage, morphology, zona pellucida thickness and implantation potential of embryos transferred on day 3 from POSEIDON and non-POSEIDON patients.
J Obstet Gynaecol Res
February 2025
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Başkent University Hospital, Ankara, Turkey.
Aim: To investigate if there is any benefit of adding clomiphene citrate (CC) + letrozole to controlled ovarian stimulation (COS) cycles on the total gonadotropin dose in POSEIDON group 4 diminished ovarian reserve (DOR) patients.
Methods: A total of 61 DOR patients who underwent 150 COS cycles between 2020 and 2023 in our center were investigated retrospectively. The patients were divided into three main subgroups: group A, group B, and group C.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!